EA201592261A1 - Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой - Google Patents

Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой

Info

Publication number
EA201592261A1
EA201592261A1 EA201592261A EA201592261A EA201592261A1 EA 201592261 A1 EA201592261 A1 EA 201592261A1 EA 201592261 A EA201592261 A EA 201592261A EA 201592261 A EA201592261 A EA 201592261A EA 201592261 A1 EA201592261 A1 EA 201592261A1
Authority
EA
Eurasian Patent Office
Prior art keywords
homelatin
agomelatin
crystals
pharmaceutical compositions
agomelatine
Prior art date
Application number
EA201592261A
Other languages
English (en)
Inventor
Ярослав Резац
Мартин Новак
Даниэль Прибиль
Анна Гановска
Людек Ридван
Александра Думициц
Владимир Краль
Original Assignee
Зентива, К.С.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зентива, К.С. filed Critical Зентива, К.С.
Publication of EA201592261A1 publication Critical patent/EA201592261A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid

Abstract

Фармацевтическая композиция, включающая агомелатин в форме сокристаллов агомелатина с образователем сокристаллов, выбранным из группы органических кислот в количестве, соответствующем дозе агомелатина от 15 до 22 мг на одну дозированную единицу, и по меньшей мере один фармацевтически приемлемый эксципиент для эффективного лечения заболеваний, поддающихся терапии агомелатином.
EA201592261A 2013-06-06 2014-05-24 Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой EA201592261A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13002931.7A EP2810647A1 (en) 2013-06-06 2013-06-06 Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
PCT/EP2014/001409 WO2014194991A1 (en) 2013-06-06 2014-05-24 Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid

Publications (1)

Publication Number Publication Date
EA201592261A1 true EA201592261A1 (ru) 2016-05-31

Family

ID=48606993

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201592261A EA201592261A1 (ru) 2013-06-06 2014-05-24 Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой

Country Status (9)

Country Link
EP (1) EP2810647A1 (ru)
JP (1) JP2016520628A (ru)
KR (1) KR20160014618A (ru)
CN (1) CN105407882A (ru)
BR (1) BR112015030388A2 (ru)
EA (1) EA201592261A1 (ru)
MX (1) MX2015016678A (ru)
WO (1) WO2014194991A1 (ru)
ZA (1) ZA201508860B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3466413A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Pharmaceutical composition containing agomelatine and process for the preparation thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2795326B1 (fr) 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
FR2834890B1 (fr) 2002-01-23 2004-02-27 Servier Lab Composition pharmaceutique orodispersible d'agomelatine
FR2866335B1 (fr) 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2889522B1 (fr) 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iv de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889523B1 (fr) 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2889521B1 (fr) 2005-08-03 2007-12-28 Servier Lab Nouvelle forme cristalline iii de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2890562B1 (fr) 2005-09-09 2012-10-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime
FR2894475B1 (fr) 2005-12-14 2008-05-16 Servier Lab Composition pharmaceutique orodispersible pour administra- -tion oromucosale ou sublinguale d'agomelatine
FR2899472B1 (fr) 2006-04-07 2008-09-12 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du trouble anxiete generalisee
FR2908994B1 (fr) * 2006-11-24 2009-04-03 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement de la leucomalacie periventriculaire
FR2908995B1 (fr) * 2006-11-24 2009-02-06 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis
FR2923482B1 (fr) 2007-11-09 2010-01-29 Servier Lab Nouvelle forme cristalline vi de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
CN102106807B (zh) 2009-12-29 2013-03-27 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
CN101991559B (zh) 2010-11-25 2012-04-18 天津市汉康医药生物技术有限公司 一种稳定的阿戈美拉汀胶囊药物组合物
EP2517700B1 (en) * 2011-04-28 2013-07-17 Zentiva, k.s. Pharmaceutically acceptable cocrystals of N-[2-(7-methoxy-1-naphthyl]acetamide and methods of their preparation
PH12012000132A1 (en) * 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
FR2976284B1 (fr) * 2011-06-09 2013-05-24 Servier Lab Nouveaux co-cristaux d'agomelatine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP2551257A1 (en) * 2011-07-28 2013-01-30 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of agomelatine with co-crystal-formers

Also Published As

Publication number Publication date
CN105407882A (zh) 2016-03-16
EP2810647A1 (en) 2014-12-10
JP2016520628A (ja) 2016-07-14
MX2015016678A (es) 2016-08-08
ZA201508860B (en) 2017-08-30
WO2014194991A1 (en) 2014-12-11
KR20160014618A (ko) 2016-02-11
BR112015030388A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
JP2012193216A5 (ru)
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
IN2015DN00376A (ru)
IN2012DN06720A (ru)
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
RU2019110980A (ru) Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
EA201592261A1 (ru) Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
CU20130004A7 (es) Agentes terapéuticos 976
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
CY1121280T1 (el) Χρηση της θυαζολοπυριμιδινονης για τη θεραπεια της φλεγμονωδους νοσου του εντερου
RU2013126798A (ru) Комбинированная терапия дексаметазоном
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically
MX2016006375A (es) Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro.
EA201200799A1 (ru) Гепатопротекторное средство
AR098924A1 (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y teriflunomida